Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

Stephanie J. Lee, Manisha Kukreja, Tao Wang, Sergio A. Giralt, Jeffrey Szer, Mukta Arora, Ann E. Woolfrey, Francisco Cervantes, Richard E. Champlin, Robert Peter Gale, Joerg Halter, Armand Keating, David I. Marks, Philip L. McCarthy, Eduardo Olavarria, Edward A. Stadtmauer, Manuel Abecasis, Vikas Gupta, H. Jean Khoury, Biju George & 13 others Gregory A. Hale, Jane L. Liesveld, David A. Rizzieri, Joseph H. Antin, Brian J. Bolwell, Matthew H. Carabasi, Edward Copelan, Osman Ilhan, Mark R. Litzow, Harold C. Schouten, Axel R. Zander, Mary M. Horowitz, Richard Maziarz

Research output: Contribution to journalArticle

98 Citations (Scopus)

Abstract

Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM +) and 900 subjects who did not receive IM before HCT (IM -) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatmentrelated mortality, relapse, leukemia-free survival, or survival. Acute graft-versushost disease rates were similar between IM + and IM - groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.

Original languageEnglish (US)
Pages (from-to)3500-3507
Number of pages8
JournalBlood
Volume112
Issue number8
DOIs
StatePublished - Oct 15 2008

Fingerprint

Cell Transplantation
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Transplants
Grafts
Bone
Blood
Survival
Leukemia
Matched-Pair Analysis
Recurrence
Mortality
Imatinib Mesylate
Therapeutics
Bone Marrow Transplantation
Survival Rate
Bone Marrow
Tissue Donors
Research

ASJC Scopus subject areas

  • Hematology
  • Biochemistry
  • Cell Biology
  • Immunology

Cite this

Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. / Lee, Stephanie J.; Kukreja, Manisha; Wang, Tao; Giralt, Sergio A.; Szer, Jeffrey; Arora, Mukta; Woolfrey, Ann E.; Cervantes, Francisco; Champlin, Richard E.; Gale, Robert Peter; Halter, Joerg; Keating, Armand; Marks, David I.; McCarthy, Philip L.; Olavarria, Eduardo; Stadtmauer, Edward A.; Abecasis, Manuel; Gupta, Vikas; Khoury, H. Jean; George, Biju; Hale, Gregory A.; Liesveld, Jane L.; Rizzieri, David A.; Antin, Joseph H.; Bolwell, Brian J.; Carabasi, Matthew H.; Copelan, Edward; Ilhan, Osman; Litzow, Mark R.; Schouten, Harold C.; Zander, Axel R.; Horowitz, Mary M.; Maziarz, Richard.

In: Blood, Vol. 112, No. 8, 15.10.2008, p. 3500-3507.

Research output: Contribution to journalArticle

Lee, SJ, Kukreja, M, Wang, T, Giralt, SA, Szer, J, Arora, M, Woolfrey, AE, Cervantes, F, Champlin, RE, Gale, RP, Halter, J, Keating, A, Marks, DI, McCarthy, PL, Olavarria, E, Stadtmauer, EA, Abecasis, M, Gupta, V, Khoury, HJ, George, B, Hale, GA, Liesveld, JL, Rizzieri, DA, Antin, JH, Bolwell, BJ, Carabasi, MH, Copelan, E, Ilhan, O, Litzow, MR, Schouten, HC, Zander, AR, Horowitz, MM & Maziarz, R 2008, 'Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia', Blood, vol. 112, no. 8, pp. 3500-3507. https://doi.org/10.1182/blood-2008-02-141689
Lee, Stephanie J. ; Kukreja, Manisha ; Wang, Tao ; Giralt, Sergio A. ; Szer, Jeffrey ; Arora, Mukta ; Woolfrey, Ann E. ; Cervantes, Francisco ; Champlin, Richard E. ; Gale, Robert Peter ; Halter, Joerg ; Keating, Armand ; Marks, David I. ; McCarthy, Philip L. ; Olavarria, Eduardo ; Stadtmauer, Edward A. ; Abecasis, Manuel ; Gupta, Vikas ; Khoury, H. Jean ; George, Biju ; Hale, Gregory A. ; Liesveld, Jane L. ; Rizzieri, David A. ; Antin, Joseph H. ; Bolwell, Brian J. ; Carabasi, Matthew H. ; Copelan, Edward ; Ilhan, Osman ; Litzow, Mark R. ; Schouten, Harold C. ; Zander, Axel R. ; Horowitz, Mary M. ; Maziarz, Richard. / Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia. In: Blood. 2008 ; Vol. 112, No. 8. pp. 3500-3507.
@article{d73753f05f2c423480e2f2a36bad47f1,
title = "Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia",
abstract = "Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM +) and 900 subjects who did not receive IM before HCT (IM -) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatmentrelated mortality, relapse, leukemia-free survival, or survival. Acute graft-versushost disease rates were similar between IM + and IM - groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.",
author = "Lee, {Stephanie J.} and Manisha Kukreja and Tao Wang and Giralt, {Sergio A.} and Jeffrey Szer and Mukta Arora and Woolfrey, {Ann E.} and Francisco Cervantes and Champlin, {Richard E.} and Gale, {Robert Peter} and Joerg Halter and Armand Keating and Marks, {David I.} and McCarthy, {Philip L.} and Eduardo Olavarria and Stadtmauer, {Edward A.} and Manuel Abecasis and Vikas Gupta and Khoury, {H. Jean} and Biju George and Hale, {Gregory A.} and Liesveld, {Jane L.} and Rizzieri, {David A.} and Antin, {Joseph H.} and Bolwell, {Brian J.} and Carabasi, {Matthew H.} and Edward Copelan and Osman Ilhan and Litzow, {Mark R.} and Schouten, {Harold C.} and Zander, {Axel R.} and Horowitz, {Mary M.} and Richard Maziarz",
year = "2008",
month = "10",
day = "15",
doi = "10.1182/blood-2008-02-141689",
language = "English (US)",
volume = "112",
pages = "3500--3507",
journal = "Blood",
issn = "0006-4971",
publisher = "American Society of Hematology",
number = "8",

}

TY - JOUR

T1 - Impact of prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia

AU - Lee, Stephanie J.

AU - Kukreja, Manisha

AU - Wang, Tao

AU - Giralt, Sergio A.

AU - Szer, Jeffrey

AU - Arora, Mukta

AU - Woolfrey, Ann E.

AU - Cervantes, Francisco

AU - Champlin, Richard E.

AU - Gale, Robert Peter

AU - Halter, Joerg

AU - Keating, Armand

AU - Marks, David I.

AU - McCarthy, Philip L.

AU - Olavarria, Eduardo

AU - Stadtmauer, Edward A.

AU - Abecasis, Manuel

AU - Gupta, Vikas

AU - Khoury, H. Jean

AU - George, Biju

AU - Hale, Gregory A.

AU - Liesveld, Jane L.

AU - Rizzieri, David A.

AU - Antin, Joseph H.

AU - Bolwell, Brian J.

AU - Carabasi, Matthew H.

AU - Copelan, Edward

AU - Ilhan, Osman

AU - Litzow, Mark R.

AU - Schouten, Harold C.

AU - Zander, Axel R.

AU - Horowitz, Mary M.

AU - Maziarz, Richard

PY - 2008/10/15

Y1 - 2008/10/15

N2 - Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM +) and 900 subjects who did not receive IM before HCT (IM -) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatmentrelated mortality, relapse, leukemia-free survival, or survival. Acute graft-versushost disease rates were similar between IM + and IM - groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.

AB - Imatinib mesylate (IM, Gleevec) has largely supplanted allogeneic hematopoietic cell transplantation (HCT) as first line therapy for chronic myeloid leukemia (CML). Nevertheless, many people with CML eventually undergo HCT, raising the question of whether prior IM therapy impacts HCT success. Data from the Center for International Blood and Marrow Transplant Research on 409 subjects treated with IM before HCT (IM +) and 900 subjects who did not receive IM before HCT (IM -) were analyzed. Among patients in first chronic phase, IM therapy before HCT was associated with better survival but no statistically significant differences in treatment-related mortality, relapse, and leukemia-free survival. Better HLA-matched donors, use of bone marrow, and transplantation within one year of diagnosis were also associated with better survival. A matched-pairs analysis was performed and confirmed a higher survival rate among first chronic phase patients receiving IM. Among patients transplanted with advanced CML, use of IM before HCT was not associated with treatmentrelated mortality, relapse, leukemia-free survival, or survival. Acute graft-versushost disease rates were similar between IM + and IM - groups regardless of leukemia phase. These results should be reassuring to patients receiving IM before HCT.

UR - http://www.scopus.com/inward/record.url?scp=54049146732&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=54049146732&partnerID=8YFLogxK

U2 - 10.1182/blood-2008-02-141689

DO - 10.1182/blood-2008-02-141689

M3 - Article

VL - 112

SP - 3500

EP - 3507

JO - Blood

JF - Blood

SN - 0006-4971

IS - 8

ER -